FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Cresco Labs, Inc. (the “Issuer”).

Trading Symbol: CL.CN

Number of Outstanding Listed Securities: 46,719,648 Subordinate Voting Shares

Date: July 5th, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Issuer Response:** Updates about the Company’s business are available under the Company's profile on SEDAR at www.sedar.com and on Cresco’s investors website at investors.crescolabs.com.

On June 12th, 2019, the Company announced the opening of new VidaCann medical cannabis dispensaries in the cities of Pensacola and Jacksonville, Florida. With the opening of the new dispensaries, VidaCann now has 12 operating dispensaries throughout the state of Florida. Cresco Labs has entered into an agreement to acquire the ownership interests of VidaCann, one of the largest and most advanced providers of medical cannabis in Florida. The acquisition of VidaCann is expected to close within the next 30 to 90 days, subject to the satisfaction of customary closing conditions including approval by the Florida Department of Health.

*Please refer to the Issuer’s News release dated June 12th, 2019*

1. Provide a general overview and discussion of the activities of management.

**Issuer Response:** Management has been actively involved in managing the operations and revenue growth, as well as exploring and evaluating expansion opportunities.

On June 11th, 2019, the Company provided an update on its acquisition (the “Transaction”) of CannaRoyalty Corp. d/b/a Origin House (“Origin House” – CSE: OH, OTCQX: ORHOF). Under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), Cresco Labs is required to file a notification to U.S. antitrust authorities and observe a waiting period before completing the Transaction. On June 10, 2019, pursuant to the HSR Act, the Company received a request for additional information (the “Second Request”) from the United States Department of Justice Antitrust Division (the “Department of Justice”). The Second Request extends the HSR Act waiting period for up to 30 days after Cresco Labs and Origin House have each substantially complied with the Second Request, unless that period is extended voluntarily by the parties or terminated sooner by the Department of Justice

*Please refer to the Issuer’s News release dated June 11th, 2019*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Issuer Response:** No new products or services developed or offered during June.

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Issuer Response:** None.

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Issuer Response:** During June, the Company did not enter into any material contracts, joint venture agreements or licensing agreements.

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Issuer Response:** Not applicable.

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Issuer Response:**  During June, the Issuer did not make any acquisitions or dispositions.

1. Describe the acquisition of new customers or loss of customers.

**Issuer Response:** The Issuer continues to seek customer growth through strategic acquisitions, as well as organically through product expansion and increased product availability.

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Issuer Response:** During June, the Issuer did not experience any new developments or effects on intangible assets.

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Issuer Response:** There were no material hirings or terminations during June and there are no anticipated lay-offs*.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

**Issuer Response:** Not applicable.

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Issuer Response:** None.

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Issuer Response:** None.

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
| Options  | 745,000 | 6/30/2019 | No cash proceeds |
| Subordinate Voting Shares | 10,000 | Warrants Exercised on 06/17/2019 | C$85,000 cash proceeds will be used in the normal course of business |

1. *State aggregate proceeds and intended allocation of proceeds.*

Note: Stock options above are included in the allocation in the Company’s 2018 Annual Information Form, filed with SEDAR on May 9, 2019.

1. Provide details of any loans to or by Related Persons.

**Issuer Response:** There are no changes to report.

1. Provide details of any changes in directors, officers or committee members.

**Issuer Response:** There are no changes to report.

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

On June 3rd, 2019, the Company provided comments on the passage of legislation on June 2, 2019 that makes Illinois’ medical-use cannabis program permanent, expands the list of qualifying medical conditions, and allows for nurse practitioners and physician’s assistants to certify a patient’s eligibility for the program in addition to doctors.

*Please refer to the Issuer’s News release dated June 3rd, 2019*

On June 11th, 2019 the Company provided an update on its Illinois operations following Governor JB Pritzker’s signing into law of the legalization of adult-use cannabis in Illinois beginning on January 1, 2020.

*Please refer to the Issuer’s News release dated June 25th, 2019*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 5th, 2019.

 Ken Amann
Name of Director or Senior Officer

 /s/ Ken Amann
Signature

Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerCresco Labs, Inc. | For Month EndJune 2019 | Date of ReportYY/MM/D19/7/5 |
| Issuer Address400 W Erie St., Suite 110 |
| City/Province/Postal CodeChicago, Illinois 60654 | Issuer Fax No. | Issuer Telephone No.312-929-0993 |
| Contact NameKen Amann | Contact PositionCFO | Contact Telephone No.312-929-0993 |
| Contact Email Addresskena@crescolabs.com | Web Site Addresshttps://www.crescolabs.com |